Impact of Xiaoyan Lidan Tablets Combined with Cefoperazone Sulbactam on Inflammatory Factor Indicators in Patients with Acute Cholecystitis
Objective To explore the impact of Xiaoyan Lidan tablets combined with cefoperazone sulbactam on inflammatory factor indicators in patients with acute cholecystitis.Methods 70 patients with acute cholecystitis admitted to our hospital from January 2020 to December 2022 were selected and randomly divided into two groups,with 35 cases in each group.The control group was treated with cefoperazone sulbactam,while the observation group was treated with Xiaoyan Lidan tablets on the basis of the control group.Both groups were treated for 1 month continuously.The clinical efficacy,inflammatory factor indicators,and incidence of adverse reactions were compared between two groups.Results The total effective rate of treatment in the observation group was higher than that in the control group(P<0.05).After treatment,the IL-6,CRP and TNF-α levels of the observation group were lower than those of the control group(P<0.05).No statistical difference was found in the incidence of adverse reactions between the two groups(P>0.05).Conclusions Xiaoyan Lidan tablets combined with cefoperazone sulbactam has significant effect in the treatment of patients with acute cholecystitis,and can improve the inflammatory response status of patients,without significant adverse reactions,which has high clinical application safety.
国家科技期刊平台
NSTL
万方数据
